Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Prepares To Begin Search For Drug Safety Issues At Molecular Level

This article was originally published in The Pink Sheet Daily

Executive Summary

Combination of new science and technology could allow drug developers to identify molecular risk targets, much as they look for therapeutic targets, agency tells advisory panel.

You may also be interested in...



FDA Expands Safety Signal Assessment With Mechanism-Based System

FDA will work with MolecularHealth Inc. to adapt the company’s software system, which combines molecular data with clinical data, to allow mechanism-based assessment of side effects.

FDA Looking At Genetic Factors In Vaccine Safety With New Research Group

FDA's latest target in its genomics research is vaccine safety, with a new effort to investigate how genetics contribute to vaccine reactions. The agency has hired staff and started work on strategic plans for a new, dedicated team within the Center for Biologics Evaluation and Research

FDA Looking At Genetic Factors In Vaccine Safety With New Research Group

FDA's latest target in its genomics research is vaccine safety, with a new effort to investigate how genetics contribute to vaccine reactions. The agency has hired staff and started work on strategic plans for a new, dedicated team within the Center for Biologics Evaluation and Research

Topics

UsernamePublicRestriction

Register

PS070374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel